Briefing: 3 Advances Driving Oncology Clinical Trial Success
Precision subject matter expert Pat Devitt examines the 3 advances driving oncology clinical trial success in a special editorial for STAT News.
Tomas Philipson Participates in AEI Panel on Pricing of Specialty Drugs
On Monday, September 12th, 2016 at AEI, health policy experts representing practitioners and industry discussed the issue of high drug prices.
On the panel, Precision Health Economics’ Tomas Philipson cast doubt on the claim that research and development determine pricing, arguing that in reality causality runs in the opposite direction. He noted potential flaws in value-based pricing and a one-size-fits-all-approach to global drug development and argued for more robust credit markets in health care.
Commentary: Value Frameworks Are Here: What To Do About Them?
Precision Health Economics’ Senior Research Economist Jason Shafrin provides an in-depth analysis of value frameworks in a new article for Pharmaceutical Commerce.
Commentary: To Prevent Another EpiPen Controversy, the Government Should Step In
Precision Health Economics’ Dana Goldman addresses the firestorm created by Mylan’s dramatic price hikes for their EpiPen in a new commentary published in STAT News: “To Prevent Another EpiPen Controversy, the Government Should Step In.”
Commentary: Concierge Care Can Help Indigent Uninsured
Precision Health Economics’ Dana Goldman offers his latest opinion piece for the New York Times,”Hospital Care for Those Who Can Afford It Helps Care for Those Who Can’t.” In his commentary, Dr. Goldman suggests that concierge care may paradoxically be the best hope for ensuring continued access to healthcare for the indigent uninsured.